Myriad Genetics | MYGN - Sales Revenues

Stock Price
3.65
Daily Change
0.07 1.96%
Monthly
-28.99%
Yearly
-17.61%
Q2 Forecast
3.51

Myriad Genetics reported $200.4M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agilent USD 1.8B 63M Dec/2025
Becton, Dickinson and Co. USD 4.7B 600M Mar/2026
Bio-Rad Laboratories USD 592.1M 101.1M Mar/2026
Bruker USD 823.4M 153.8M Mar/2026
Danaher USD 5.95B 890M Mar/2026
Illumina USD 1.09B 70M Mar/2026
J&J USD 24.1B 500M Mar/2026
Mettler Toledo International USD 947.13M 182.87M Mar/2026
Myriad Genetics USD 200.4M 9.4M Mar/2026
OraSure Technologies USD 26.76M 322K Dec/2025
Pacific Biosciences Of California USD 44.64M 6.2M Dec/2025
Quest Diagnostics USD 2.9B 90M Mar/2026
Quidel USD 620M 104M Mar/2026
Repligen USD 194M 3.91M Mar/2026
Revvity USD 711M 61.06M Mar/2026
Standard Biotools USD 21.1M 2.7M Mar/2026
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Veracyte USD 139.07M 1.53M Mar/2026
Waters USD 1.27B 338M Mar/2026